

# Apostolos Tsapas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7286575/publications.pdf>

Version: 2024-02-01

149  
papers

18,712  
citations

71102

41  
h-index

11939

134  
g-index

156  
all docs

156  
docs citations

156  
times ranked

17153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-dipping pattern in early-stage diabetes: association with glycemic profile and hemodynamic parameters. Journal of Human Hypertension, 2022, 36, 805-810.	2.2	5
2	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114.	4.4	19
3	The relationship between early symptom severity, improvement and remission in first episode psychosis with jumping to conclusions. Schizophrenia Research, 2022, 240, 24-30.	2.0	4
4	Reporting completeness in abstracts of systematic reviews of diagnostic test accuracy studies in cardiovascular diseases is suboptimal. Hellenic Journal of Cardiology, 2022, 65, 25-34.	1.0	4
5	Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events. Clinical Nutrition, 2022, 41, 923-930.	5.0	8
6	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261.	6.3	93
7	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension, 2021, 34, 404-413.	2.0	7
8	Methods for depicting overlap in overviews of systematic reviews: An introduction to static tabular and graphical displays. Journal of Clinical Epidemiology, 2021, 132, 34-45.	5.0	52
9	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831.	4.4	17
10	Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. Heart, 2021, 107, 150-158.	2.9	25
11	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2021, 174, 141.	3.9	1
12	KDIGO made 12 recommendations for managing diabetes with CKD. Annals of Internal Medicine, 2021, 174, JC26.	3.9	1
13	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737.	2.8	61
14	Fluid volume regulation in patients with heart failure. Lancet Diabetes and Endocrinology, the, 2021, 9, 257-258.	11.4	0
15	MO642DAPAGLIFLOZIN HAS NO IMPACT ON SHORT-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
16	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2116-2124.	4.4	79
17	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2395-2401.	4.4	18
18	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921.	2.8	10

#	ARTICLE	IF	CITATIONS
19	TIMER: A Clinical Study of Energy Restriction in Women with Gestational Diabetes Mellitus. <i>Nutrients</i> , 2021, 13, 2457.	4.1	8
20	Add-on interventions for the prevention of recurrent <i>Clostridioides Difficile</i> infection: A systematic review and network meta-analysis. <i>Anaerobe</i> , 2021, 71, 102441.	2.1	6
21	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Hypertension</i> , 2021, 39, 749-758.	0.5	38
22	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	4.4	54
23	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 221-228.	6.3	368
24	Patients <sup>™</sup> and Clinicians <sup>™</sup> Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , 2020, , 1.	2.6	7
25	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	8.6	846
26	Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers. <i>Annals of Internal Medicine</i> , 2020, 172, JC27.	3.9	4
27	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	3.9	182
28	Some glucose-lowering drugs reduce risk for major adverse cardiac events. <i>Annals of Internal Medicine</i> , 2020, 173, JC9.	3.9	3
29	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. <i>Annals of Internal Medicine</i> , 2020, 173, JC70.	3.9	0
30	P1026 THE EFFECT OF DAPAGLIFLOZIN ON 24-HOUR BLOOD PRESSURE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
31	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	4.4	44
32	SO036 THE EFFECT OF DAPAGLIFLOZIN ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
33	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	4.4	33
34	Carvedilol for prevention of variceal bleeding: a systematic review and meta analysis. <i>Annals of Gastroenterology</i> , 2019, 32, 287-297.	0.6	13
35	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1744-1755.e11.	4.4	84
36	Guidelines for Medical Nutrition Therapy in Gestational Diabetes Mellitus: Systematic Review and Critical Appraisal. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2019, 119, 1320-1339.	0.8	36

#	ARTICLE	IF	CITATIONS
37	Decreased cortisol response to low-dose Synacthen test in pediatric patients with type 1 diabetes. Journal of Diabetes, 2019, 11, 773-774.	1.8	0
38	Prevention of orthodontic enamel demineralization: A systematic review with meta-analyses. Orthodontics and Craniofacial Research, 2019, 22, 225-235.	2.8	45
39	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	1.9	10
40	Intravenous Magnesium Sulfate in Acute Stroke. Stroke, 2019, 50, 931-938.	2.0	17
41	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. Diabetic Medicine, 2019, 36, 557-568.	2.3	9
42	Omega-3 Supplementation And Cardiovascular Disease: Meta-Analysis With Trial Sequential Analysis. Atherosclerosis, 2019, 287, e284.	0.8	1
43	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. Journal of Hypertension, 2019, 37, 2307-2324.	0.5	66
44	The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. Journal of Hypertension, 2019, 37, 1334-1343.	0.5	43
45	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2549-2557.	2.4	6
46	Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 517-524.	4.4	23
47	P670 Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Journal of Crohn's and Colitis, 2018, 12, S449-S450.	1.3	0
48	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews, 2018, 23, 377-388.	3.9	16
49	Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. Clinical Drug Investigation, 2018, 38, 417-426.	2.2	34
50	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310.	2.3	294
51	Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. Journal of Clinical Epidemiology, 2018, 93, 9-24.	5.0	177
52	Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin, 2018, 42, 339-341.	0.8	22
53	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
54	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	6.3	1,002

#	ARTICLE	IF	CITATIONS
55	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	8.6	2,190
56	Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Alimentary Pharmacology and Therapeutics, 2018, 48, 1174-1185.	3.7	41
57	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Annals of Gastroenterology, 2018, 31, 572-582.	0.6	19
58	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2255-2263.	4.4	71
59	In type 2 diabetes, weekly semaglutide reduced HbA <sub>1c</sub> and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine, 2018, 168, JC46.	3.9	1
60	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Annals of Internal Medicine, 2018, 169, 165.	3.9	38
61	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
62	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. European Journal of Haematology, 2017, 98, 563-568.	2.2	10
63	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine, 2017, 56, 485-494.	2.3	15
64	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 843-851.	1.8	19
65	Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer. JAMA Internal Medicine, 2017, 177, 1110.	5.1	63
66	Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. Annals of Hematology, 2017, 96, 1937-1944.	1.8	11
67	Meta-analysis of artificial pancreas trials: methodological considerations. Lancet Diabetes and Endocrinology, 2017, 5, 685.	11.4	2
68	Budget Impact Analysis of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece. Value in Health, 2017, 20, A476.	0.3	2
69	Cost-Effectiveness of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece. Value in Health, 2017, 20, A479.	0.3	0
70	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10.	4.7	5
71	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Dermato-Venereologica, 2017, 97, 1145-1147.	1.3	10
72	P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Journal of Crohn's and Colitis, 2017, 11, S418-S419.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. <i>BMJ Open</i> , 2016, 6, e012185.	1.9	18
74	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	2.0	0
75	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 2016, 54, 620-633.	2.3	4
76	A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. <i>Journal of Vascular Surgery</i> , 2016, 63, 22S-28S.e2.	1.1	92
77	A systematic review and meta-analysis of off-loading methods for diabetic foot ulcers. <i>Journal of Vascular Surgery</i> , 2016, 63, 59S-68S.e2.	1.1	62
78	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	27.0	208
79	A systematic review and meta-analysis of tests to predict wound healing in diabetic foot. <i>Journal of Vascular Surgery</i> , 2016, 63, 29S-36S.e2.	1.1	116
80	A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. <i>Journal of Vascular Surgery</i> , 2016, 63, 46S-58S.e2.	1.1	71
81	A systematic review and meta-analysis of debridement methods for chronic diabetic foot ulcers. <i>Journal of Vascular Surgery</i> , 2016, 63, 37S-45S.e2.	1.1	59
82	Premixed insulin regimens for type 2 diabetes. <i>Endocrine</i> , 2016, 51, 387-389.	2.3	2
83	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , 2016, 52, 458-480.	2.3	42
84	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 36-38.	2.4	13
85	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 241.	3.9	1
86	Efficacy and safety of once-a-week glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	4.4	61
87	Systematic reviews with language restrictions and no author contact have lower overall credibility: a methodology study. <i>Clinical Epidemiology</i> , 2015, 7, 243.	3.0	21
88	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	6.3	598
89	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. <i>Diabetes Management</i> , 2015, 5, 119-125.	0.5	2
90	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 61-67.	3.2	26

#	ARTICLE	IF	CITATIONS
91	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	8.6	2,326
92	Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 55-63.e5.	4.4	49
93	Investigating the role of Natural Killer T-cells in Gram negative infections of patients with type 2 diabetes mellitus. Hippokratia, 2015, 19, 231-4.	0.3	1
94	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety, 2014, 5, 138-146.	2.4	96
95	Medical student recognition of benign anorectal conditions: the effect of attending the outpatient colorectal clinic. BMC Surgery, 2014, 14, 95.	1.3	2
96	Pharmacologic Interventions for Painful Diabetic Neuropathy. Annals of Internal Medicine, 2014, 161, 639.	3.9	148
97	Review: Sodium-glucose cotransporter 2 inhibitors reduce HbA <sub>1c</sub> and weight but increase infections. Annals of Internal Medicine, 2014, 160, JC10.	3.9	1
98	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2014, 16, 984-993.	4.4	176
99	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2014, 63, 584-592.	3.4	27
100	Non-dipping Status in Arterial Hypertension: An Overview. Current Vascular Pharmacology, 2014, 12, 527-536.	1.7	14
101	Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 262.	3.9	749
102	Basing information on comprehensive, critically appraised, and up-to-date syntheses of the scientific evidence: a quality dimension of the International Patient Decision Aid Standards. BMC Medical Informatics and Decision Making, 2013, 13, S5.	3.0	60
103	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379. Diabetes Care, 2013, 36, 490-490.	8.6	130
104	Systematic reviews supporting practice guideline recommendations lack protection against bias. Journal of Clinical Epidemiology, 2013, 66, 633-638.	5.0	23
105	Large- and Small-for-Gestational-Age Neonates Born by Women with Gestational Diabetes Mellitus Diagnosed by the New IADPSG Criteria: a Case-Control Study of 289 Patients and 1 108 Controls. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 262-265.	1.2	10
106	Safety And Efficacy Of 4 Years Of Deferasirox Treatment For Sickle Cell Disease Patients. Hemoglobin, 2013, 37, 94-100.	0.8	6
107	Methodology for Quantifying Fasting Glucose Homeostasis in Type 2 Diabetes: Observed Variability and Lability. Journal of Diabetes Science and Technology, 2013, 7, 640-645.	2.2	3
108	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012, 25, 154-171.	1.0	28



#	ARTICLE	IF	CITATIONS
109	Common Variants in <i>FTO</i> , <i>MC4R</i> , <i>TMEM18</i> , <i>PRL</i> , <i>AIF1</i> , and <i>PCSK1</i> Show Evidence of Association With Adult Obesity in the Greek Population. <i>Obesity</i> , 2012, 20, 389-395.	3.0	56
110	Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis (Protocol). <i>Systematic Reviews</i> , 2012, 1, 61.	5.3	9
111	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	8.6	3,077
112	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e1369-e1369.	2.3	356
113	Authors' reply to Scheffel and Schaan. <i>BMJ, The</i> , 2012, 344, e2922-e2922.	6.0	1
114	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	6.3	1,718
115	Safety of deferasirox in sickle cell disease patients with coexisting liver impairment. <i>British Journal of Haematology</i> , 2012, 157, 505-506.	2.5	0
116	Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes. <i>Annals of Internal Medicine</i> , 2012, 156, JC1.	3.9	1
117	Effect of Epinephrine and Insulin Resistance on Human Monocytes Obtained From Lean and Obese Healthy Participants: A Pilot Study. <i>Angiology</i> , 2011, 62, 38-45.	1.8	8
118	Effect of Glucose and Insulin on Oxidized Low-Density Lipoprotein Phagocytosis by Human Monocytes: A Pilot Study. <i>Angiology</i> , 2011, 62, 163-166.	1.8	5
119	Leptin, Adiponectin, and Insulin Resistance. <i>Angiology</i> , 2011, 62, 349-349.	1.8	0
120	Accuracy of the Neuropad Test for the Diagnosis of Distal Symmetric Polyneuropathy in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1378-1382.	8.6	38
121	Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous $\beta^0$ -Thalassemia?. <i>Angiology</i> , 2011, 62, 346-348.	1.8	5
122	Glycemia and cardiovascular risk: challenging evidence based medicine. <i>Hippokratia</i> , 2011, 15, 199-204.	0.3	3
123	Review: Metformin does not increase risk for lactic acidosis in type 2 diabetes. <i>Annals of Internal Medicine</i> , 2010, 153, JC1.	3.9	3
124	Effect of Leptin and Insulin Resistance on Properties of Human Monocytes in Lean and Obese Healthy Participants. <i>Angiology</i> , 2010, 61, 768-774.	1.8	13
125	Glycaemic Control is Correlated with Well-Being Index (WHO-5) in Subjects with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 364-367.	1.2	36
126	Na <sup>+</sup> /H <sup>+</sup> -exchanger-1: a link with atherogenesis?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1545-1556.	4.1	10



#	ARTICLE	IF	CITATIONS
127	The Protective Role of the Mediterranean Diet on the Prevalence of Metabolic Syndrome in a Population of Greek Obese Subjects. Journal of the American College of Nutrition, 2010, 29, 41-45.	1.8	38
128	Involvement of Signaling Molecules on Na <sup>+</sup> /H <sup>+</sup> Exchanger-1 Activity in Human Monocytes. Open Cardiovascular Medicine Journal, 2010, 4, 181-188.	0.3	11
129	Gestational diabetes mellitus: why screen and how to diagnose. Hippokratia, 2010, 14, 151-4.	0.3	20
130	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, 6423.	0.4	10
131	Monocyte attachment to laminin in diabetes mellitus. Cell Adhesion and Migration, 2009, 3, 155-159.	2.7	3
132	Using N-of-1 Trials in Evidence-Based Clinical Practice. JAMA - Journal of the American Medical Association, 2009, 301, 1022.	7.4	12
133	Intensive insulin therapy reduced long-term risk for incident hypertension in type 1 diabetes. Annals of Internal Medicine, 2009, 150, JC2.	3.9	0
134	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, .	0.4	1
135	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, .	0.4	0
136	N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia, 2008, 51, 921-925.	6.3	46
137	Female fertility and colorectal cancer. International Journal of Colorectal Disease, 2008, 23, 735-743.	2.2	49
138	Eosinophilic pneumonia associated with heroin inhalation: a case report. Wiener Klinische Wochenschrift, 2008, 120, 178-180.	1.9	13
139	Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenous leukemia (CML). Leukemia Research, 2008, 32, 674-675.	0.8	16
140	Association between BBS6/MKKS gene polymorphisms, obesity and metabolic syndrome in the Greek population. International Journal of Obesity, 2008, 32, 1618-1625.	3.4	10
141	Diabetic cardiomyopathy: a controversial entity. European Heart Journal, 2008, 29, 564-564.	2.2	6
142	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes and Vascular Disease Research, 2008, 5, 216-218.	2.0	40
143	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. Diabetes Research and Clinical Practice, 2007, 76, 468-469.	2.8	0
144	Enhanced laminin carbonylation by monocytes in diabetes mellitus. Clinical Biochemistry, 2007, 40, 671-679.	1.9	20

#	ARTICLE	IF	CITATIONS
145	PO014 In vitro growth modulation by L-ascorbic acid (L-AA) of colony forming cells from bone marrow of patients with refractory anemia (RA). Leukemia Research, 2007, 31, S135-S136.	0.8	0
146	Insulin sensitivity assessment with euglycemic insulin clamp in adult $\beta^2$ -thalassaemia major patients. European Journal of Haematology, 2007, 79, 526-530.	2.2	8
147	Yersinia enterocolitica O:3 mesenteric lymphadenopathy in an apparently healthy adult. Netherlands Journal of Medicine, 2007, 65, 311-2.	0.5	4
148	Septicemia caused by Oligella urethralis in a patient with end-stage cancer. Clinical Microbiology Newsletter, 2006, 28, 30-31.	0.7	1
149	Cariporide Counteracts Atherosclerosis-Related Functions in Monocytes from Obese and Normal Individuals. Obesity, 2005, 13, 1588-1595.	4.0	9